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ABSTRACT
The Editorial Board have prepared a podcast
describing their experiences over the past year
of the COVID-19 pandemic. The Editorial Board
describe how COVID-19 impacted their research
and how the initial clinical response changed
over the course of the year in terms of treat-
ment, personal protective equipment (PPE), and
policy changes. The podcast and transcript can
be viewed below the abstract of the online ver-
sion of the manuscript. Alternatively, the pod-
cast and transcript can be downloaded here:
https://doi.org/10.6084/m9.figshare.14402291
Keywords: COVID-19; Podcast; Pulmonary;
Respiratory; Vaccine
INTRODUCTION
Hello, and thank you for listening to the Pul-
monary Therapy podcast on COVID-19—Supplementary Information The online version
contains supplementary material available at https://
doi.org/10.1007/s41030-021-00157-6.
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Research and Real-World Experiences from the
Editorial Board. My name is Christopher Vau-
trinot and I am the managing editor of the
journal. Together with a number of the jour-
nal’s Editorial Board members, we have com-
piled clips, submitted by the board, who
describe their experience over the past year of
the COVID-19 pandemic. The Editorial Board
describe how COVID-19 impacted their research
and how the initial clinical response changed
over the course of the year in terms of treat-
ment, PPE [personal protective equipment] and
policy changes. We hope you find the podcast
informative and useful.
KAI MICHAEL BEEH
Hi, everybody. My name is Kai Michael Beeh. I
am a pulmonologist from Germany in Wies-
baden. I am the medical director of the insaf
Respiratory Research Institute and I also lead a
private pulmonology practice. I am one of the
editors of the journal Pulmonary Therapy.
So, can you tell us how COVID has impacted
your research? COVID had quite a striking
impact on my work both as a clinician but also
as a researcher. Now, as you may know, in my
institute we do a lot of clinical trials in
obstructive airway diseases, namely asthma and
COPD, so there was a lot of that work that was
delayed, put on hold, or even sometimes
abruptly discontinued due to the outbreak of
the pandemic. So there was a great deal of
uncertainty and also quite a period where we
actually totally had to adjust our organisation of
research there, taken together with the fact that
many patients were quite insecure when the
pandemic started: how to behave, how they
would continue with their visits and so on. So it
was quite a big interruption of our normal work.
Second question, how did COVID impact
your clinic during the initial outbreak? Well,
there were a lot of measures that had to be
installed during the initial outbreak. First of all,
we reduced measurements with the potential of
aerosol generation like forced spirometry, par-
ticularly airway challenge and sputum induc-
tions, stuff like that. We were starting to equip
staff, but also ourselves of course, with personal
protective equipment, and after a while we got
used to this new situation, and then of course
with the precautions, and also some evidence
coming up that certain measures could be
installed to actually minimise the risk of infec-
tion, or spread of COVID would be effective.
After this came through we were more and more
confident to perform measurements also with
our patients on site. So currently we are in a
situation where we are doing most things quite
regularly and quite normally but under, of
course, a strict regime of precautionary
measures.
The third question, what lessons have been
learned so far? Well, both as a researcher and as
a clinician, the most positive lesson of the last
year was the rapid development of a very
effective vaccine, in fact, different very effective
vaccines. I think that was really a type of a best
way or best world scenario that this happened
so fast, and we were able to roll out vaccines
already at the end of 2020. Although of course
the logistical challenges seem to be far more
important than the medical aspects of vaccina-
tion, but that’s something, of course another
lesson that we need to learn. What I found quite
disappointing was the relatively poor outcome
of actually the COVID treatments, so the clini-
cal trials performed in a number of agents that
provided some hope of efficacy versus COVID-
19. They have been largely disappointing, and
also the quality of research in total sometimes
was quite disappointing. So there were many
studies with few patients, quite often under-
powered, not properly enrolling, not properly
organised and also structured clinical trial pro-
tocols. So I think it’s very important, a lesson to
be learned is that we need to be better prepared
and we need to have protocols and platforms
installed in case of pandemics.
NAZIA CHAUDHURI
Hi. My name’s Nazia Chaudhuri. I’m an inter-
stitial lung disease specialist in Manchester in
the United Kingdom. I am also a research lead
for interstitial lung disease in Manchester.
So one of the first questions is how has
COVID impacted my research? Well, during the
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first wave in March, we were very much all
redeployed to the wards because of the sheer
number of patients on our wards. So initially
there was a massive impact on our research. All
our research, particularly in idiopathic pul-
monary fibrosis, was put on hold because all our
research staff were also redeployed to the wards.
This has had a massive impact obviously on the
access of research trials for our patients, but
similarly, our patients were also shielding and
were told to stay away from the hospital, and
stay safe, and stay at home. So our patients also
weren’t very keen on coming to the hospital for
their research trials. Our focus very much shif-
ted to the RECOVERY trial and delivering
COVID-related research, and certainly Manch-
ester is one of the highest recruiters in COVID-
related research in the United Kingdom. But as
we came out of the first wave, even though we
are now into our second wave, thankfully, the
impact on research hasn’t been as great. So,
research for patient needs, particularly related
to idiopathic pulmonary fibrosis where our
patients don’t have any other treatment
options, is allowed to continue. So we are cer-
tainly continuing to recruit to the GALACTIC
trial and we have a number of patients who
have recently been screened and recruited to
that. Unfortunately, the GALAPOGAS trial was
put on hold. So hopefully we are hoping to get
back on track with our research and invite our
patients, in a safe environment, to continue
with regards to access to research trials.
So the next question is, how did COVID
impact my clinic during the initial outbreak?
Well, again, unfortunately, in the first wave all
our clinics were cancelled for the first few
months, just because the sheer number of
patients we had as inpatients on the wards in
March. But, thankfully, from July onwards we
have been able to reinstate our interstitial lung
disease clinics, but we’ve reinstated them in
different ways. We are certainly working very
differently now during this COVID pandemic.
All our clinics are now virtual. We are using
virtual platforms were we can phone our
patients with video consultations and assess our
patients virtually—negating the need to bring
our patients to big, busy waiting rooms. In
Manchester we have approximately ten clinic
rooms going on at the same time in a small
confined area in the morning and the after-
noon, and you can imagine that would be in
excess of 100 patients in the morning and
afternoon, and certainly we can’t socially dis-
tance. So most of our clinics are now virtual. We
are inviting patients we are concerned about for
face-to-face consultations. COVID had a mas-
sive impact on our lung function capacity.
Again, due to the AGP (aerosol-generating pro-
cedures), we had to have increased time
between our lung function procedures, and so
that really reduced our capacity. We’ve used
innovative ways of increasing our lung function
capacity by working out of different areas
around the trust. Providing lung function and
also providing lung function in community
hospitals so that patients can come elsewhere
for their lung function, and slowly but surely, as
we come out of the pandemic, we are increasing
our capacity. Obviously we are all wearing full
PPE in our clinics with masks and gloves and
aprons, and we are very much socially distanc-
ing our patients, so that we are timing their
attendance to clinics so that there is minimal
contact with other people.
So the next question is, how has this initial
reaction to the pandemic developed over time
and what lessons have been learnt? Well cer-
tainly, thankfully, for interstitial lung disease,
one of our key thoughts was to continue our
access to treatments for our patients who have
debilitating symptoms as well as bad prognosis,
for example our patients with idiopathic pul-
monary fibrosis. So we have maintained our
access to antifibrotics by performing virtual
clinics. By relying on our local physicians to
make sure that they’ve done all the lung func-
tion and blood tests so the patient is ready
when they come to see us. We are performing a
one-stop shop for our patients, particularly for
our new patients. We are able to perform our
new patient assessments in a non-COVID area
in our hospital so patients can come and feel
safe. They can feel safe that they are away from
our COVID areas. We adhere to full PPE proce-
dures with hand gel and masks so our patients
feel safe, and so we have learnt that we can
maintain our outpatient practice as much as
possible during this pandemic, and certainly we
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have not cancelled all our outpatient activity,
and tried to resume and very much have tried to
catch up with our outpatient activity. For
interstitial lung disease, thankfully, there have
been some policy changes. So, for example, in
the UK, you always had to have an up-to-date
lung function for prescribing antifibrotics,
because we have a restriction with an FVC
[forced vital capacity] of 50–80%, and thank-
fully NHS England agreed that as long as that
lung function was in 12 months that we could
use historic lung function, and that was really
to the benefit of our patients, to ensure they got
timely access to treatments, particularly antifi-
brotics. We perform a lot of virtual monitoring
clinics, so our pharmacists and our specialist
nurses perform a lot of virtual monitoring
clinics so that we can maintain safe prescribing
of immunosuppressants such as mycophenolate
and our antifibrotics. So, all in all, the COVID
pandemic has been very challenging but I think
we have worked our way through. We have
provided our patients, on an outpatient per-
spective, safe care so that they can have con-
tinued care in our interstitial lung disease
service. We are now seeing light at the end of
the tunnel, and hopefully with the vaccination
rollout, we will see the case numbers of COVID
in the community decrease so our patients feel
confident that they can come to the hospital for
their clinic appointments. But certainly COVID
will change our future way of working, and we
will work more virtually in the future, as well as
with our patient, but also from an educational
perspective as well.
TIMOTHY J CRAIG
So, hello. I’m Dr. Timothy Craig. I’m from Penn
State University. which is in Pennsylvania, USA.
I’m an allergist immunologist in a pulmonary
group. I focus on rare diseases: alpha-1 antit-
rypsin, hereditary angioedema and common
variable immunodeficiency. In addition, the
majority of my work, despite specializing in
orphan diseases, is actually in asthma. I’ve been
doing this for 25 years. We have a large section
of allergy in the pulmonary group and I think
we provide really good services.
So, one of the questions that came up was
how did COVID affect our research? So, you
know, it’s been strange over the year here—I
guess, a year and a few months. So, at first,
everything shut down, but then what hap-
pened, we were able to start recruiting patients
for clinical trials phase 2 and 3s. And, actually, I
thought it worked out well because a lot of
patients actually had free time, they didn’t have
to go to work or they were working from home,
and so it was easy to recruit patients to come
into our clinical trials. Unfortunately, any other
trial where there wasn’t any benefit to the
patients such as phase 4s and some, just labo-
ratory collection, went poorly, and we had to
cease recruitment for those studies and actually
had to stop them. In addition, we were doing
some basic research work on a microRNA, and
unfortunately, we had to stop that too; how-
ever, we finally got that going about 3–-
4 months ago. So, right now, we’re back up, and
our basic research also, and we’ve continued for
clinical research. And lastly, for the phase 4s
and other studies that really had no benefit to a
patient, we’ve been able to start them about a
month ago. So, in some ways, it impacted us,
but in some ways, that actually worked out well
for us.
You know, similarly for clinic, you know,
how it impacted our clinic, we went 100% vir-
tual up first. Unfortunately, with that we had to
stop doing pulmonary function tests and almost
all our procedures. And with that, our income
drops significantly, and the amount of patients
that we saw stayed. It’s just that the reim-
bursements for telehealth was much less. How-
ever, we did really well. We switched to a
platform, an official platform, called Amwell,
and so actually, almost 100%—I shouldn’t say—
I think it was 95% were actually on a telehealth
platform, which allowed for better reimburse-
ment than just a phone conversation with the
patient. So I think we were, we did good on that
conversion.
But then we started opening up, once we got
over the first wave, and we opened up, and we
decided to do 50/50—50% clinic and 50% tele-
health—so that we could have more procedures.
And that’s worked out well. My no-show rate’s
been minimal, but my colleagues had a fair
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amount of no shows, and in fact, if you looked
at the data, there was less no shows for tele-
health than there was in face-to-face clinic. So,
we’re still now—even though we’re not in
another wave, but even between these two
waves, or surge, whatever you want to refer to it
as—we still are 50/50, because those statistics
demonstrate in that people were more likely to
show up for a telehealth visit. So, it’s been an
interesting time. I personally prefer face-to-face,
and I am going to be moving in that direction as
fast as I can. Probably by July, I’ll do all face-to-
face. But I know my colleagues, some of them
enjoy telehealth more, and they’ll probably still
stay in that—that 50/50 ratio.
One of the things with this, though, is that
we still haven’t got spirometry and some of the
other testing we do—exhaled nitric oxide—up,
so because of not having the proper filters and
our spirometer and not having a room that is
negative pressure. So that’s going to be, that is a
large part of our income, and we’ll have to some
way find a way to modify that. Not only is it
income, though, for following COPD and
asthma patients without spirometry is for me
very difficult. So, you know, I think that how
we’ve really kind of emerged from this is, you
know, from the beginning of the pandemic to
now is that we really gathered confidence that
we can do telehealth. And I feel good about it
and feel that we’re doing a good job. So that’s
pretty rewarding. It has, however, impacted our
bottom line, which is, you know, in a univer-
sity, that’s very important. We have to support
our employees and everything else. But I think
the majority of us now that we’re vaccinated at
least feel a lot more confident, you know,
moving back into the face-to-face visits by—
maybe that’s a false sense of security in some
ways, but, you know, it’s nice too to be able to
have some face-to-face meetings. It’s nice to be
able to drink a cup of coffee in my office, which
is a shared office, the clinical office at least. And
I think that my research, nurses, it’s really been
a nice building up confidence for them now
that they’re vaccinated and the same above
clinic nurses. Unfortunately, not all our clinic
nurses have got vaccinated, but our policy in
the hospital, much to my dismay, is that you
can’t ask anybody if they’ve been vaccinated
because of a HIPAA violation.
But I do think that if we continue to vacci-
nate like the federal government and United
States wants us to, that come this summer it
may be very appropriate to start doing every-
thing we have in the past done before the
pandemic. So, good opportunity, good learning.
So, yeah, for our patients we’ve lost, we lost
quite a few here, mainly more family and
friends than actually my patients. But from
everything bad, comes some good points. With
that, you know, I wish you all good luck, and
please be safe out there. And I hope that these
times, even though they’ve been trying, that
you gain some fortune from it. And I guess with
fortune, is sounds like more a gain, but you’ve
at least obtained some information to better
your life, and like you do in your clinic and your
research. So, thank you for this opportunity,
and have a great day.
ALAN KAPLAN
Hello. My name is Dr. Alan Kaplan, a family
physician from Toronto, Canada. I’m the chair
of the Family Physician Airways Group of
Canada, a vice president of the Respiratory
Effectiveness Group and an honorary professor
of primary care research of the Observational &
Pragmatic Research Institute in Singapore.
How has COVID impacted my research?
Well, clearly, in-person studies are on hold.
Virtual assessments, however, do allow surveys
and behavioural research. Initially the issues are
mostly of COVID on respiratory issues. I think
our next big issue is going to be in primary care,
but how we deal with long haulers.
How did COVID impact my clinic during the
initial outbreak? Well, clearly, we had to have
screening done before anyone was actually
seen, although most things were done virtually
initially, and the government did step up to
create virtual fee codes. We used masks and
goggles and handwashing for low risk, moving
up to PPE and N95 for people with high risk.
More recently we’ve reinstituted spirometry
testing with screening done first, the rooms
cleaned post-op and PPE for the staff as well.
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How has this initial reaction to the pandemic
developed over time? Well, clearly, we learnt
about social distancing, with particular concern
about both aerosol and surface spread. We
learnt that asymptomatic carriers can and will
spread the illness. We know that people are the
most infectious before they become sick, or
early in the illness. The risk of severe COVID is
clearly an important issue; age, obesity, smok-
ers, who tend to have more ACE receptors, car-
diovascular illness, COPD, diabetes, etc.
Interestingly, though it’s not related to ACE
inhibitors, it’s not related to inhaled corticos-
teroid use. So, we really shouldn’t change any-
thing in terms of prevention, and actually the
best thing to do is to keep patients controlled in
their conditions to prevent the severe COVID.
Lastly, we have vaccinations, which are not
quite being done as frequently or as compre-
hensively across the population as they should
be yet, but that’s our hope for the future with
respect to COVID-19. Thank you.
MARCUS PETER KENNEDY
Hi. My name is Dr. Marcus Kennedy, and I’m a
consultant respiratory physician and interven-
tional pulmonologist at Cork University
Hospital Ireland. My area of interest is lung
cancer and interventional pulmonology.
The first question is, how has COVID
impacted my research? COVID has impacted
my research. Our group has a research interest
in bronchoscopy, including single-use bron-
choscopy, and we were investigating this new
technology prior to the COVID pandemic. The
COVID pandemic has brought this technology
to the forefront. There are a number of clinical
scenarios where single-use flexible broncho-
scopes have advantages, and reasons for this
include ease of mobility, allowing bron-
choscopy in the ICU, bronchoscopy in the
emergency department and emergency bron-
choscopy outside the health care facility, and all
these indications were brought to the forefront
with the COVID pandemic. These scopes are
practical, allowing out-of-hours bronchoscopy,
allowing bronchoscopy at the end of a day list
where staff are not required to clean scopes.
These also allow weekend bronchoscopy staff
who are not available to clean scopes. They are
also used in specific scenarios including
immunocompromised patients and a patient
with prion disease, where in the past a reusable
scope would have to be destroyed after being
used on a patient with prion disease. They are
also important for scope training, for veterinary
procedures and large animal and cadaveric
research. Particularly in the era of COVID, these
scopes have advantages in that they don’t need
to be cleaned. They are completely sterile when
put into the patient, and there is a concern that
a reusable scope may cross-contaminate COVID
from one patient to another. In patients with
COVID, the advantage of not having to clean a
scope would reduce the risk of contamination
from the patient with COVID to the health care
worker who is cleaning the scope.
The next question is, how did COVID impact
your clinic during the initial outbreak? As a
respiratory physician I was at the forefront of
looking after sick patients with COVID. Access
for other respiratory patients to services
including lung cancer patients and COPD
patients was clearly negatively impacted at the
outset of the COVID pandemic.
How has this initial reaction to the pandemic
developed over time and what lessons have
been learnt? Our hospital group was at the
forefront of wave 3 of COVID in Ireland from
January to February 2021. Our hospital group
became involved in international studies in
COVID-19 treatment. Our group learned how to
separate COVID and non-COVID care and thus
maintain critical non-COVID services, includ-
ing lung cancer.
OUTRO
That brings us to the end of our Pulmonary
Therapy podcast on COVID-19 ‘‘Research and
Real-World Experiences from the Editorial
Board’’. Thank you for listening, and thanks to
all of the Editorial Board members who con-
tributed—Drs. Kai Michael Beeh, Nazia Chaud-
huri, Timothy Craig, Alan Kaplan and Marcus
Kennedy. Thank you very much.
Pulm Ther
ACKNOWLEDGEMENTS
Funding. No funding or sponsorship was
received for this study or publication of this
article.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Disclosures. Dr. Kai-Michael Beeh and/or
the institution Dr. Beeh represents have
received compensation for services on advisory
boards or consulting for AstraZeneca, Berlin
Chemie, Boehringer, Chiesi, GSK, Novartis,
Pohl Boskamp, TEVA and sterna, and compen-
sation for speaker activities in scientific meet-
ings supported by AstraZeneca, Berlin Chemie,
Boehringer, Cytos, ERT, GSK, Novartis, Pfizer,
Pohl Boskamp, and TEVA. The institution has
further received compensation for design and
performance of clinical trials from AstraZeneca,
Boehringer, GSK, Novartis, Parexel, Pearl Ther-
apeutics, and sterna. Nazia Chaudhuri has
received research grants from BI and Roche and
has done consultancy work for BI, Roche,
Novartis and Redex. Timothy Craig declares the
following: Research-Regeneron, GSK, Grifols,
CSL Behring, Takeda, BioMarin, Astra Zeneca,
Biocryst. Speaking-Regeneron, Grifols, CSL
Behring, Biocryst, Takeda. Consultant- Spark,
BioMarin, Novartis, Biocryst, Pharming, Takeda,
Grifols, GKK. Alan Kaplan has received support
as a speaker or Advisory Board member for
AstraZeneca, Behring, Boehringer Ingelheim,
Covis, Griffols, GSK, Novo Nordisk, Pfizer,
Sanofi, Teva and Trudell Medical. Marcus Peter
Kennedy has received educational grants for
purchasing simulators and other training
equipment valued 1-10000 Euro from The Sur-
gical Company, Cook Medical, Menarini Phar-
maceuticals and Orion Pharmaceuticals. He also
has a non-disclosure contract and current grant
applications with Boston Scientific.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with
humanparticipants or animals performed by
any of the authors.
Data Availability. Data sharing is not
applicable to this article as no datasets were
generated or analyzed during the current study.
Open Access. This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit
line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the
copyright holder. To view a copy of this licence,
visit http://creativecommons.org/licenses/by-
nc/4.0/.
Pulm Ther
